SDH-Engine — Drug Repurposing for SDH-Deficient Diseases

This tool is for research exploration only. It is not a medical device and does not provide medical advice. Drug candidates, evidence scores, and AI-generated content are not clinical recommendations. Always consult your medical team before making any treatment decisions.

Drug Candidates

38 candidates mapped to SDH-deficient disease pathways

All (38)established (6)clinical trial (5)preclinical (14)theoretical (13)

Welireg

HIF-2α inhibitor

Hif Pseudohypoxia

FDA Approved1 trial

Sutent

Multi-kinase inhibitor (VEGFR/PDGFR/KIT)

Vegf SignalingMtor Pi3k Akt

GISTPPGL/PCCRCC

FDA Approved1 trial

Pan-FGFR inhibitor (FGFR1/2/3/4)

Fgfr SignalingEpigenetic Dysregulation

Temodar, Temodal

Alkylating agent

Epigenetic Dysregulation

Avastin

Anti-VEGF monoclonal antibody

Tazverik

EZH2 inhibitor (PRC2 inhibitor)

Epigenetic Dysregulation

FDA Approved1 trial

Dacogen

DNA methyltransferase inhibitor (hypomethylating agent)

Epigenetic Dysregulation

Cabometyx, Cometriq

Multi-kinase inhibitor (VEGFR2/MET/AXL/RET/KIT)

Hif Met Axl SignalingVegf Signaling

FDA Approved2 trials

CB-839

Glutaminase inhibitor

Glutamine Dependency

Vidaza

DNA methyltransferase inhibitor (hypomethylating agent)

Epigenetic Dysregulation

Lynparza

PARP inhibitor (PARP1/2)

Sdh Driven HrdOxidative Stress Ros

Stivarga

Multi-kinase inhibitor (VEGFR/KIT/PDGFR/FGFR/RAF)

Vegf SignalingMtor Pi3k Akt

Afinitor

mTOR inhibitor (rapalog)

Daporinad (FK866)

APO866

NAMPT inhibitor (NAD⁺ biosynthesis inhibitor)

Nad MetabolismOxidative Stress Ros

Zejula

PARP inhibitor (PARP1/2)

Hydroxychloroquine

Plaquenil

Autophagy inhibitor (lysosomal alkalinizer)

Autophagy Survival

FDA Approved2 trials

Balversa

Pan-FGFR inhibitor (FGFR1/2/3/4), FDA-approved

Glucophage

Biguanide / AMPK activator

Mtor Pi3k AktOxidative Stress Ros

DENSPM (N1,N11-Diethylnorspermine)

Polyamine analogue / SSAT inducer

Polyamine MetabolismOxidative Stress Ros

Dichloroacetate (DCA)

Pyruvate dehydrogenase kinase inhibitor

Hif PseudohypoxiaOxidative Stress Ros

TVB-2640

FASN inhibitor (fatty acid synthase inhibitor)

De Novo LipogenesisGlutamine Dependency

Lutetium-177 DOTATATE

Lutathera

Peptide receptor radionuclide therapy (PRRT) / SSTR2-targeted radioligand therapy

Sstr2 Somatostatin VulnerabilitySdh Driven Hrd

FDA Approved3 trials

OTX015, MK-8628

BET bromodomain inhibitor (pan-BRD2/3/4)

Epigenetic Dysregulation

AZD6738

ATR kinase inhibitor

Atrx Alt Replication Stress

Keytruda

Anti-PD-1 monoclonal antibody (checkpoint inhibitor)

Hif Pdl1 Checkpoint EvasionSuccinate Immune Evasion

FDA Approved2 trials

Ym155 (Sepantronium Bromide)

YM155, Sepantronium

Survivin (BIRC5) transcription inhibitor / IAP inhibitor

Hif Driven Survivin ApoptosisSdh Driven Hrd

Farydak

Pan-HDAC inhibitor

Epigenetic Dysregulation

MCT1 inhibitor (monocarboxylate transporter 1 inhibitor, SLC16A1)

Succinate Immune Evasion

TAK-924

NAE inhibitor (neddylation inhibitor, NEDD8-activating enzyme inhibitor)

Ibrance

CDK4/6 inhibitor

Cdkn2a Cdk46 Cell CycleEpigenetic Dysregulation

Idhifa

IDH2 inhibitor

Epigenetic Dysregulation

DUP-785, NSC 368390

DHODH inhibitor (dihydroorotate dehydrogenase inhibitor)

Pyrimidine Synthesis Vulnerability

[212Pb]VMT-α-NET

Alpha-particle SSTR2-targeted radioligand therapy (RLT)

Sstr2 Somatostatin VulnerabilitySdh Driven Hrd

POLQ inhibitor (DNA polymerase theta inhibitor)

Polq Tmej Backup RepairSdh Driven Hrd

Eflornithine (DFMO)

Iwilfin, Ornidyl

ODC1 inhibitor (ornithine decarboxylase inhibitor / polyamine synthesis inhibitor)

Polyamine Metabolism

INCB024360

IDO1 inhibitor (indoleamine 2,3-dioxygenase 1 inhibitor)

Succinate Immune Evasion

Aubagio

DHODH inhibitor (active metabolite of leflunomide; FDA-approved)

Pyrimidine Synthesis Vulnerability

FDA Approved1 trial

Ascorbic Acid (High-dose IV)

TET enzyme cofactor / α-KG-dependent dioxygenase activator

Epigenetic DysregulationOxidative Stress Ros